CHANGES IN FIBROSIS, BUT NOT THE NAFLD ACTIVITY SCORE (NAS), ARE ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS

被引：0
|
作者：
Sanyal, Arun
Harrison, Stephen A.
Ratziu, Vlad
Abdelmalek, Manal F.
Diehl, Anna Mae
Caldwell, Stephen H.
Shiffman, Mitchell L.
Aguilar, Raul
Jia, Catherine
McColgan, Bryan J.
Natha, Macky
Myers, Robert P.
Subramanian, Mani
McHutchison, John
Muir, Andrew J.
Afdhal, Nezam H.
Bosch, Jaime
Goodman, Zachary
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)33563-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
354
引用
收藏
页码：S1055 / S1055
页数：1
相关论文
共 50 条
  • [1] Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
    Sanyal, A.
    Harrison, S.
    Ratziu, V.
    Abdelmalek, M.
    Diehl, A.
    Caldwell, S.
    Shiffman, M.
    Aguilar, R.
    Jia, C.
    McColgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Muir, A.
    Afdhal, N.
    Bosch, J.
    Goodman, Z.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S2 - S3
  • [2] Higher Rates of Disease Progression among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Fibrosis (AF) and Diabetes Mellitus (DM)
    Younossi, Zobair
    Kachru, Nandita
    Shreay, Sanatan
    Loomba, Rohit
    DIABETES, 2019, 68
  • [3] Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    Caldwell, Stephen
    Shiffman, Mitchell L.
    Ghalib, Reem
    Lawitz, Eric
    Rockey, Don C.
    Schall, Raul E. Aguilar
    Jia, Catherine
    McColgan, Bryan J.
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Muir, Andrew J.
    Ratziu, Vlad
    Afdhal, Nezam H.
    Goodman, Zachary D.
    Bosch, Jaime
    Sanyal, Arun J.
    HEPATOLOGY, 2017, 66 : 1120A - 1121A
  • [4] HEALTHCARE UTILIZATION IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) PATIENTS WITH ELEVATED NAFLD ACTIVITY SCORE (NAS): IMPACT OF FIBROSIS LEVELS
    Fishman, J.
    Calay, E. S.
    Kim, Y.
    Vu, P.
    Hegstrom, L.
    VALUE IN HEALTH, 2024, 27 (06) : S141 - S141
  • [5] Predictors of Fibrosis Progression and Regression by Histology and Morphometrically Quantified Collagen in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
    Younossi, Zobair M.
    Stepanova, Maria
    Sanyal, Arun J.
    Harrison, Stephen A.
    Ratziu, Vlad
    McColgan, Bryan J.
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Afdhal, Nezam H.
    Abdelmalek, Manal F.
    Bosch, Jaime
    Goodman, Zachary D.
    HEPATOLOGY, 2017, 66 : 1171A - 1171A
  • [6] Systematic review of fibrosis progression in nonalcoholic steatohepatitis (NASH)
    Argo, Curtis K.
    Northup, Patrick G.
    Caldwell, Stephen H.
    HEPATOLOGY, 2006, 44 (04) : 650A - 651A
  • [7] Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
    Z. Wang
    Z. Zhao
    Y. Xia
    Z. Cai
    C. Wang
    Y. Shen
    R. Liu
    H. Qin
    J. Jia
    G. Yuan
    Journal of Endocrinological Investigation, 2022, 45 : 1379 - 1392
  • [8] Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
    Wang, Z.
    Zhao, Z.
    Xia, Y.
    Cai, Z.
    Wang, C.
    Shen, Y.
    Liu, R.
    Qin, H.
    Jia, J.
    Yuan, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (07) : 1379 - 1392
  • [9] NASH SEVERITY ASSESSED BY THE NAFLD ACTIVITY SCORE (NAS) DOES NOT ADD PROGNOSTIC INFORMATION TO FIBROSIS STAGE IN PATIENTS WITH NAFLD
    Mozes, Ferenc Emil
    Kaur, Senamjit
    Vali, Yasaman
    Alzoubi, Osama
    Wong, Vincent Wai-Sun
    Li, Guanlin
    Wong, Grace Lai-Hung C.
    Staufer, Katharina
    Trauner, Michael
    Paternostro, Rafael
    Stauber, Rudolf E.
    Bugianesi, Elisabetta
    Gaia, Silvia
    Armandi, Angelo
    Lupsor-Platon, Monica
    Sebastiani, Giada
    Mahadeva, Sanjiv
    Rajaram, Ruveena
    Zheng, Ming-Hua
    George, Jacob
    Eslam, Mohammed M.
    Pennisi, Grazia
    Aithal, Guruprasad P.
    Palaniyappan, Naaventhan
    Lee, Daeho
    Nasr, Patrik
    Cassinotto, Christophe
    De Ledinghen, Victor
    Berzigotti, Annalisa
    Mendoza, Yuly Paulin
    Noureddin, Mazen
    Truong, Emily
    Boursier, Jerome
    De Saint Loup, Marc
    Hirooka, Masashi
    Shima, Toshihide
    Dr Shalimar
    Hagstrom, Hannes
    Ekstedt, Mattias
    Akbari, Camilla
    Chan, Wah Kheong
    Tsochatzis, Emmanuel A.
    Liguori, Antonio
    Petta, Salvatore
    Vigano, Mauro
    Ridolfo, Sofia
    Yoneda, Masato
    Nakajima, Atsushi
    Holleboom, Adriaan G.
    Van Dijk, Anne-Marieke
    HEPATOLOGY, 2023, 78 : S1018 - S1020
  • [10] The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
    Cichoz-Lach, Halina
    Celinski, Krzysztof
    Prozorow-Krol, Beata
    Swatek, Jaroslaw
    Slomka, Maria
    Lach, Tomasz
    MEDICAL SCIENCE MONITOR, 2012, 18 (12): : CR735 - CR740
12345